Open Access

Risk of major bleeding at different PT-INR ranges in elderly Japanese patients with non-valvular atrial fibrillation receiving warfarin: a nested case-control study

  • Atsushi Ohgushi1Email author,
  • Takayuki Ohtani1,
  • Natsumi Nakayama1,
  • Shigeo Asai1,
  • Yoshiyuki Ishii1,
  • Atsuo Namiki2,
  • Manabu Akazawa3 and
  • Hirotoshi Echizen4
Journal of Pharmaceutical Health Care and Sciences20162:2

DOI: 10.1186/s40780-015-0036-1

Received: 19 October 2015

Accepted: 21 December 2015

Published: 11 January 2016

Abstract

Background

Debate continues about the optimal anticoagulation level for elderly Japanese patients with non-valvular atrial fibrillation (NVAF) receiving warfarin. The Japanese Circulation Society guideline has recommended prothrombin time-international normalized ratios (PT-INR) of 1.6 – 2.6 for elderly patients and 2.0 – 3.0 for non-elderly patients, because previous observational studies indicated increased risk of bleeding when the ratio exceeded 2.6. We aimed to reappraise the relationship between PT-INR and the risk of major bleeding in elderly Japanese patients.

Methods

From the electronic medical records, we selected a cohort of elderly (age ≥ 70 years) Japanese patients with NVAF who were prescribed warfarin for the prevention of thromboembolic diseases between November 2010 and March 2014 at Kanto Rosai Hospital. We identified those who developed major bleeding (cases). For each case, we randomly selected two matched controls by adopting a risk-set sampling method defined by calendar date, age, gender, length of warfarin administration, and the prescriber of warfarin. The risk of major bleeding in patients having PT-INR ≤ 1.49, 1.50 – 1.99, 2.00 – 2.49 (the reference), 2.50 – 2.99, and ≥ 3.00 were compared using the conditional logistic regression method. The study protocol was approved by the IRB before the study was begun.

Results

Among the cohort of 806 elderly patients, we identified 32 cases and selected 64 matched controls. The overall incidence of major bleeding was 3.5 per 100 patient-years. The odds ratios (95 % confidence intervals) for the risk of developing major bleeding in patients with PT-INR ≤ 1.49 (n = 20), 1.50 – 1.99 (n = 32), 2.00 – 2.49 (n = 18), 2.50 – 2.99 (n = 10), and ≥ 3.00 (n = 16) were 1.0 (0.2, 5.9), 0.3 (0.1, 1.9), 1.0 (reference), 1.2 (0.2, 8.4), and 19.8 (2.0, 198.9), respectively, with a significant difference between ≥ 3.00 and reference.

Conclusions

Among elderly Japanese patients with NVAF, PT-INR 2.0 – 3.0 may be associated with a clinically permissible risk of major bleeding while PT-INR ≥ 3.00 a significant risk. Further studies are warranted to determine whether the risk of major bleeding is significantly lower for PT-INR 2.50 – 2.99 than for PT-INR ≥ 3.00.

Keywords

Non-valvular atrial fibrillation Warfarin PT-INR Japanese Elderly patients

Background

Non-valvular atrial fibrillation (NVAF) is the most prevalent arrhythmia in the elderly and poses substantial morbidity and mortality risks because of an increase in cardiogenic thromboembolic complications [1]. Oral anticoagulant therapy has been shown to be effective in reducing the risk of thromboembolic events in patients of all age groups. While many non-vitamin K antagonist oral anticoagulants (NOACs) have become available, their use for elderly patients is still limited because of a paucity of information regarding their safety profiles in the elderly population [25]. As a result, warfarin is still most frequently used in these patients. Nevertheless, debate continues regarding the optimal intensity of warfarin therapy in elderly Japanese patients with NVAF. While the prothrombin time-international normalized ratio (PT-INR) range of 2.0 – 3.0 is recommended for Caucasians regardless of age and for non-elderly Japanese patients, the range of 1.6 – 2.6 has been recommended for elderly (age ≥ 70 years) Japanese patients [610].

One of the reasons for recommending a lower PT-INR range (1.6 – 2.6) for elderly Japanese patients is that an observational study on approximately 200 Japanese NVAF patients of all ages for the secondary prevention of stroke demonstrated an increased risk of major bleeding for PT-INR ≥ 2.60 [11]. Unfortunately, the study estimated the risk of major bleeding for PT-INR ≥ 2.60 as a whole, and it remains unclear if PT-INR 2.6 – 3.0 would be associated with an increased risk compared to PT-INR 1.6 – 2.6. Recent large cohort studies conducted in Japanese patients with NVAF confirmed that PT-INR 2.0 – 3.0 should be considered the target range for non-elderly Japanese patients, considering the balance between risk of bleeding and anti-thrombotic efficacy [12]. However, there is a relative lack of information regarding the bleeding risk at PT-INR 2.6 – 3.0 in elderly Japanese patients receiving warfarin [13, 14].

A case-control study design would complement prospective randomized or cohort studies in assessing the risk of outcomes with low event rates (such as major bleeding caused by warfarin). Indeed, an optimal PT-INR range of 2.0 – 3.0 for warfarin was first proposed from case-control studies conducted by Hyleck et al. [15, 16] in the early 1990s. With the availability of electronic medical record systems in community hospitals, hospital pharmacists can now conduct case-control studies using real-world clinical data. In the present study, we aimed to assess whether elderly Japanese patients with PT-INR 2.5 – 3.0 have different risk of major bleeding compared to those with PT-INR 2.0 – 2.5 or ≥ 3.0.

Methods

Retrieving case patients developing major bleeding

The present study was performed at the Japan Labour Health and Welfare Organization Kanto Rosai Hospital with 610 beds located in an urban area of Tokyo. Patients eligible for the present study were retrieved retrospectively from the electronic medical records between November 2010 and March 2014, utilizing as indices atrial fibrillation in the diagnosis [I48 by International Statistical Classification of Diseases and Related Health Problems, 10th revision (ICD-10)] and age (≥70 years). We also extracted elderly (age ≥ 70 years) patients who were prescribed warfarin using records of the electronic prescribing system. Patient retrieved from both databases were combined. Then those who were prescribed warfarin for clinical indications other than prevention of thromboembolic events associated with NVAF were excluded to obtain the final cohort for the present case-control study.

The electronic medical records were searched for occurrence of major bleeding events in the cohort using the following ICD-10 codes as event identifiers: D69 (purpura and other hemorrhagic conditions), I60 to 62 (subarachnoid hemorrhage, intracerebral hemorrhage, and other nontraumatic intracranial hemorrhage), K25.0, .2, .4, and .6 (gastric ulcer: acute with hemorrhage or perforation, chronic with hemorrhage or perforation), K26.0, .2, .4, and .6 (duodenal ulcer: acute with hemorrhage or perforation, chronic with hemorrhage or perforation), K27.0, .2, .4, and .6 (peptic ulcer, site unspecified: acute with hemorrhage or perforation, chronic with hemorrhage or perforation), K28.0, .2, .4, and .6 (gastrojejunal ulcer: acute with hemorrhage or perforation, chronic with hemorrhage or perforation), K29.0 (acute hemorrhagic gastritis), K62.5 (hemorrhage of anus and rectum), K92.0, .1, and .2 (hematemesis, melena, gastrointestinal hemorrhage unspecified), and R04 (hemorrhage from respiratory passages). Because no consensus has been reached regarding the criteria for major bleeding, we adopted the following composite criteria by modifying that used in the RE-LY study [17]. Specifically, we considered the recorded bleeding events to be compatible with major bleeding when at least one of the following conditions was met: a reduction of blood hemoglobin level of 2 g/dL or greater from the nearest preceding value, a reduction of hemoglobin level below 8 g/dL, blood transfusion was undertaken, or bleeding events were judged to necessitate hospitalization for transfusion and other necessary therapies. Because the last criterion is less objective and may be inconsistent between attending physicians, we performed an additional analysis by excluding the cases that were considered to develop major bleeding solely based on the last criterion. Whether the cases retrieved from the databases met the criteria of major bleeding was determined by two authors independently: A.O. (pharmacist) and A.N. (physician). Data of PT-INR associated with major bleeding episodes were collected from the medical records when patients visited the outpatient clinic or emergency department. In the case of emergency, the data immediately after admission were collected.

Assignment of controls

For each case patient, we randomly assigned two control patients by adopting a risk-set sampling method defined by the calendar date of the bleeding event, age, gender, length of warfarin administration, and the prescriber of warfarin [18]. In control patients, data of PT-INR nearest to the calendar date when their corresponding case patients developed major bleeding were used.

Retrieving clinical data relevant to risk analysis

Age, gender, height, weight, estimated glomerular filtration rate (eGFR), PT-INR, warfarin doses, and other clinical data required to calculate CHADS2 and HAS-BLED scores were extracted from the medical records of the retrieved patients [19, 20]. For calculating the HAS-BLED scores we searched for anti-platelet drugs and NSAIDs. In addition, we searched for the concomitant medications which might have inhibited the metabolic activity of CYP2C9 or augmented the anticoagulation effects of warfarin. They included acetaminophen, allopurinol, amiodarone, azole antifungal drugs, cimetidine, fluoroquinolones, macrolide antibiotics, metronidazole, propafenone, SSRIs, statins, sulfa antibiotics. Labile PT-INR [percent time within the therapeutic range in total therapeutic period (TTR) < 60 %] was calculated using the Rosendaal method [21]. The method assumes that changes between consecutive PT-INR measurements are linear over time. We calculated TTR assuming that PT-INR 1.6 – 2.6 is the therapeutic range for elderly Japanese patients with NVAF according to the 2013 guideline of the Japanese Circulation Society [10]. We excluded the following periods from calculation of TTR: within 7 days after the commencement of warfarin therapy and periods when warfarin was discontinued for any reason. We calculated TTR only when the PT-INR data for more than 6 consecutive months were available and when the longest measurement intervals were less than 3 months apart.

Ethical issues

The present study was planned and conducted in compliance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement and the Declaration of Helsinki. The protocol was approved by the institutional review board of Kanto Rosai Hospital (the approval # 2014–14).

Statistical analysis

Comparisons of continuous variables were performed by paired t-test and those for categorical variables by McNemar’s test. We stratified the case and control patients into five categories according to their PT-INR values (≤1.49, 1.50 – 1.99, 2.00 – 2.49, 2.50 – 2.99, and ≥ 3.00). The risk of major bleeding for each group was evaluated by conditional logistic regression analysis and expressed as odd ratio (OR) and 95 % confidence interval (CI) versus patients with PT-INR 2.00 – 2.49 (reference).

We performed power calculation for the statistical analysis of a case-control study before we began the study, according to the method reported previously [22]. We made the assumption that approximately 10 % of control and 30 % of case patients had been exposed to PT-INR ≥ 2.60. Based on this assumption and a case-control matching ratio of 1:2, we estimated that at least 34 cases and 68 controls are required for detecting a significant difference in the risk (OR) of developing major bleeding with an α error of 5 % and a power of 80 %. In addition, we performed power calculation for a cohort study according to the method reported elsewhere [22]. We assumed that the event rates of major bleeding in patients exposed to PT-INR ≥ 2.60 and < 2.60 were 15 % and 3 % person-years, respectively, according to the data reported in previous study [14] and that the size ratio between the former and latter group was 1:9. A p value less than 0.05 was considered statistically significant throughout the study. The analysis was performed using JMP Pro v.11 software (SAS Institute Inc., Cary, NC, USA).

Results

Seven hundred and sixty-nine elderly patients who were diagnosed with atrial fibrillation were extracted from the electronic medical records. In addition, 1,048 elderly patients prescribed warfarin were extracted from the prescription record database. Combining the two sets of data and collating overlapping patients, we identified 1,122 elderly patients who had atrial fibrillation and/or had received warfarin. Excluding 316 patients who were prescribed warfarin for clinical indications other than atrial fibrillation or who had valvular heart disease, the final study cohort comprised 806 elderly Japanese patients with NVAF who received warfarin (Fig. 1). Among a total of 918 person-years on warfarin therapy in the cohort, we identified 32 major bleeding events (3.5 per 100 patient-years) including 16 gastrointestinal hemorrhages, 8 intracranial hemorrhages, 5 coagulation disorders, and 3 respiratory tract hemorrhages. The number of case patients largely met the estimated size by power calculation. The demographic and clinical characteristics of the case and control patients are listed in Table 1. No significant differences in CHADS2 and HAS-BLED scores were observed between the two groups. The CHADS2 and HAS-BLED scores (both, 3 ± 1) were identical in the two groups. In addition, there was no significant difference in the numbers of patients receiving CYP2C9 inhibitors or those augment anticoagulation effect of warfarin: 17 of 32 (53 %) cases and 35 of 64 (55 %) controls ingested at least one of the above drugs by McNemar’s test. The PT-INR (median; interquartile range) for the cases (2.62; 1.97 – 5.30) was significantly (p < 0.05) greater than the ratio for the controls (1.75; 1.52 – 2.14) (Fig. 2). While approximately 50 % of the case patients showed PT-INR ≥ 2.60, only approximately 10 % of the control patients showed PT-INR ≥ 2.60 (OR 11.8; 95 % CI, 3.8 – 37.1). Collectively, these data largely agree with the preconditions for power calculation.
Fig. 1

Flowchart of the retrieval, collation and integration of patient data

Table 1

Clinical characteristics of case and control patients

Characteristics

Cases (n = 32)

Controls (n = 64)

P value

Age (yr), mean ± SD

81 ± 5

81 ± 5

NS

Gender, M/F

14/18

28/36

NS

PT-INR

   

Median PT-INR(Q1,Q3)

2.62 (1.97, 5.30)

1.75 (1.52, 2.14)

<0.05

≤1.49, n (%)

5 (16)

15 (24)

NS

1.50 to 1.99, n (%)

3 (9)

29 (45)

<0.05

2.00 to 2.49, n (%)

5 (16)

13 (20)

NS

2.50 to 2.99, n (%)

4 (12)

6 (9)

NS

≥3.00, n (%)

15 (47)

1 (2)

<0.05

eGFR (mL/min/1.73 m2), mean ± SD

43 ± 27

49 ± 15

NS

CHADS2 score, mean ± SD

3 ± 1

3 ± 1

NS

Congestive heart failure, n (%)

19 (59)

19 (30)

<0.05

Hypertension, n (%)

22 (69)

50 (78)

NS

Diabetes, n (%)

5 (16)

21 (33)

NS

Stroke/TIA, n (%)

16 (50)

23 (36)

NS

HAS-BLED score, mean ± SD

3 ± 1

3 ± 1

NS

Impaired renal function, n (%)

7 (22)

3 (5)

<0.05

Impaired liver function, n (%)

4 (13)

3 (5)

NS

Stroke, n (%)

14 (44)

22 (34)

NS

History of bleeding, n (%)

10 (31)

14 (22)

NS

Labile PT-INR, n (%)

2 (6)

19 (30)

NS

Antiplatelet or NSAID, n (%)

12 (38)

24 (38)

NS

Alcohol consumption, n (%)

1 (3)

4 (6)

NS

Q1 and 3 represent the upper limits of the first and third interquartile ranges. TIA transient ischemic attack, PT-INR prothrombin time-international normalized ratio, eGFR estimated glomerular filtration rate, NSAID non-steroidal anti-inflammatory drug

Fig. 2

Distribution of prothrombin time-international normalized ratio (PT-INR) in control and case patients. Median PT-INR (interquartile range) for case and control patients are 2.62 (1.97 – 5.30) and 1.75 (1.52 – 2.14), respectively. A significant difference is detected by paired t-test

When the risk of developing major bleeding in patients with different PT-INR ranges were compared using the risk for PT-INR 2.00 – 2.49 as reference (OR = 1), ORs for patients with PT-INRs 2.50 – 2.99, 1.50 – 1.99, and ≤ 1.49 were not significantly different from the reference, whereas OR for patients with PT-INR ≥ 3.00 was significantly (p < 0.05) greater than that of the reference (Fig. 3).
Fig. 3

Comparisons of odds ratios (ORs) and 95 % confidence intervals for developing major bleeding stratified by prothrombin time-international normalized ratio (PT-INR). The horizontal bars indicate 95 % confidence intervals (CIs) calculated by the conditional logistic regression method

In addition, the result of power calculation for a cohort study revealed that one-year follow-up of at least 400 patients (16 patients expected to develop major bleeding) is required to obtain sufficient power for detecting a significant difference in the risk of bleeding between patients exposed to PT-INR ≥ 2.60 and those exposed to < 2.60.

Five patients were considered to develop major bleeding solely by the criterion of clinical judgement of the necessity of admission. When the statistical analysis was performed by excluding these data, essentially similar results were obtained (data are not shown).

Discussion

To the best of our knowledge, this is the first nested case-control study carried out to assess the relationship between PT-INR and the risk of developing major hemorrhage in elderly Japanese patients with NVAF receiving warfarin. Our data show that patients having PT-INR ≥ 3.00 had approximately 20 times greater risk of developing major bleeding compared to patients having PT-INR 2.00 – 2.49 (reference), whereas those with PT-INR 2.50 – 2.99 appeared to have similar risk (OR 1.23) compared to the reference. Our data support the notion that the upper limit of target PT-INR for elderly Japanese patients with NVAF may be extended to 3.00. Target PT-INR of 2.0 – 3.0 has been recommended for non-elderly Japanese patients. It is noteworthy that both case and control patients participating in the present study had a high risk of thromboembolic complications, because the mean age of both groups was 81 years and both had a median CHADS2 score of 3 [19]. In addition, they had a high risk of bleeding during anticoagulation therapy because of their ages and HAS-BLED scores (Table 1). In this context, they represent elderly patients in the real-world and therefore the results of the present study would be relevant to daily medical practice.

Our data in general agree with previous studies. A subgroup analysis of elderly (age ≥ 70 years) patients in the J-Rhythm registry showed that the hazard ratio (95 % CI) of major bleeding in patients with PT-INR 2.00 – 2.59, 2.60 – 2.99, and ≥ 3.00 increased gradually to 2.87 (1.12 – 7.35), 3.99 (1.33 – 11.89), and 7.02 (2.23 – 22.13), respectively, against those who did not receive warfarin. Nevertheless, the 95 % CIs of these groups overlapped substantially [12]. Naganuma et al. conducted a cohort study of 845 elderly Japanese patients with NVAF and found that those with PT-INR ≥ 3.00 had remarkably higher incidence of major bleeding (20 per patient-year) compared to those with PT-INR 2.00 – 2.49 (1.5 per patient-year) and 2.50 – 2.99 (3.4 per patient-year) [14]. However, the 95 % CI for PT-INR 2.50 – 2.99 (95 % CI, 0.9 – 8.5) overlapped substantially with that for 2.00 – 2.49 (95 % CI, 0.6 – 3.2). Collectively, we speculate that it would be practically impossible to obtain statistically significant difference in major bleeding risk between PT-INR 1.6 – 2.6 and 2.6 – 3.0. In contrast, it may be possible to detect a significant difference in bleeding risk between the target PT-INR (irrespective of 1.6 – 2.6 or 2.0 – 3.0) and PT-INR higher than 3.0. To achieve such purpose, a case-control study design is useful, and was used by Hylek et al. [15, 16] to establish the current target PT-INR 2.0 – 3.0 for Caucasians. We calculated that the present study comprising 96 patients had comparable statistical power as a cohort study of 400 patients. Thus a case-control study would be more practicable than a cohort study to estimate the risk of drugs in a special population such as the elderly.

The present study has several drawbacks. First, we were unable to analyze the risk of intracranial hemorrhage at different PT-INR levels separately, because only a small number of events (n = 8) were observed in our cohort. A recent study has reported that the risk of intracranial hemorrhage in elderly Japanese may increase approximately four-fold (OR 4.2; 95 % CI, 1.8 – 9.8) at PT-INR 2.5 – 3.0 [13]. Ultimately, the optimal target PT-INR for elderly patients with NVAF should be estimated in light of all-cause mortality as reported by Oden and Fahlen [23]. They performed a medical record linkage study in 42,451 Caucasian patients and found that patients with PT-INR 2.0 – 2.4, 2.5 – 2.9, and 3.0 – 3.4 had all-cause mortalities of 42.3, 47.4, and 67.9 per 1,000 patient-years, respectively. At present, no such data are available for the Japanese population. Second, the present study has insufficient numbers of cases for estimating OR with narrow 95 % CI ranges in patients with the PT-INR ≥ 3.0, primarily because the study was conducted in a single medical center. Third, we did not examine the genetic polymorphisms of VKORC1 and CYP2C9 which are known to influence on the inter-individual variability and risk of bleeding in patients receiving warfarin. As a result, we cannot make any inference on the contribution of these factors to the risk of bleeding. Finally, we cannot analyze the relationship between PT-INR and thrombotic events for warfarin in the present study. For such a purpose we needed to collect cases developing thrombotic events and matched controls.

Conclusion

The present study demonstrates that PT-INR 2.0 – 3.0 may be associated with a clinically permissible risk of major bleeding while PT-INR ≥ 3.00 a significant risk in elderly Japanese patients with NVAF. The present study warrants further case-control studies with a greater number of patients to obtain conclusive evidence.

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Hospital Pharmacy, Japan Labour Health and Welfare Organization Kanto Rosai Hospital
(2)
Department of Cardiology, Japan Labour Health and Welfare Organization Kanto Rosai Hospital
(3)
Department of Public Health and Epidemiology, Meiji Pharmaceutical University
(4)
Department of Pharmacotherapy, Meiji Pharmaceutical University

References

  1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–8.View ArticlePubMedGoogle Scholar
  2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.View ArticlePubMedGoogle Scholar
  3. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.View ArticlePubMedGoogle Scholar
  4. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.View ArticlePubMedGoogle Scholar
  5. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.View ArticlePubMedGoogle Scholar
  6. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, et al. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. Circ Cardiovasc Qual Outcomes. 2009;2(4):297–304.PubMed CentralView ArticlePubMedGoogle Scholar
  7. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, et al. Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):546S–92.View ArticlePubMedGoogle Scholar
  8. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–429.View ArticleGoogle Scholar
  9. Japanese Circulation Society. Guidelines for management of anticoagulant and antiplatelet therapy in cardiovascular disease (JCS 2009). http://www.j-circ.or.jp/guideline/pdf/JCS2009_hori_h.pdf. Accessed 7 Jan 2016.
  10. Japanese Circulation Society. Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013). http://www.j-circ.or.jp/guideline/pdf/JCS2013_inoue_h.pdf. Accessed 7 Jan 2016.
  11. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med. 2001;40(12):1183–8.View ArticlePubMedGoogle Scholar
  12. Yamashita T, Inoue H, Okumura K, Atarashi H, Origasa H, J-RHYTHM Registry Investigators. Warfarin anticoagulation intensity in Japanese nonvalvular atrial fibrillation patients: a J-RHYTHM Registry analysis. J Cardiol. 2015;65(3):175–7.View ArticlePubMedGoogle Scholar
  13. Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H, J-RHYTHM Registry Investigators. Use of Warfarin in Elderly Patients With Non-Valvular Atrial Fibrillation. Subanalysis of the J-RHYTHM Registry. Circ J. 2015. [Epub ahead of print].Google Scholar
  14. Naganuma M, Shiga T, Sato K, Murasaki K, Hashiguchi M, Mochizuki M, et al. Clinical outcome in Japanese elderly patients with non-valvular atrial fibrillation taking warfarin: a single-center observational study. Thromb Res. 2012;130(1):21–6.View ArticlePubMedGoogle Scholar
  15. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120(11):897–902.View ArticlePubMedGoogle Scholar
  16. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335(8):540–6.View ArticlePubMedGoogle Scholar
  17. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975–83.View ArticlePubMedGoogle Scholar
  18. Miettinen O. Estimability and estimation in case-referent studies. Am J Epidemiol. 1976;103(2):226–35.PubMedGoogle Scholar
  19. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–70.View ArticlePubMedGoogle Scholar
  20. Lip GY. Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation. Am J Med. 2011;124(2):111–4.View ArticlePubMedGoogle Scholar
  21. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236–9.PubMedGoogle Scholar
  22. Strom BL. Sample size considerations for pharmacoepidemiology studies. In: Strom BL ed. Pharmacoepidemiology 4th ed. Chichester: Wiley; 2005, p. 29-36, p.840-857.Google Scholar
  23. Odén A, Fahlén M. Oral anticoagulation and risk of death: a medical record linkage study. BMJ. 2002;325(7372):1073–5.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Ohgushi et al. 2016

Advertisement